The OVCA2 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the OVCA2 tumor suppressor gene is disrupted in the AGS gastric adenocarcinoma cell line. This pooled knockout model provides a genetically heterogeneous population of cells with loss-of-function mutations in OVCA2, enabling robust functional studies without the clonal artifacts associated with single-cell-derived lines. The polyclonal format maintains biological variability while ensuring efficient target-gene disruption, making it suitable for investigating OVCA2-dependent phenotypes in a gastric cancer context.
The AGS cell line, derived from a human gastric adenocarcinoma, serves as a well-established model for gastric cancer research. These adherent epithelial cells recapitulate key features of gastric carcinoma and are widely employed to study oncogenic signaling, drug responses, and tumor suppressor functions. Their gastric epithelial origin makes them particularly relevant for examining genes involved in gastrointestinal malignancies, complementing studies originally linked to ovarian cancer where OVCA2 was first identified.
OVCA2 encodes a pro-apoptotic protein that acts as a tumor suppressor, primarily through its involvement in the regulation of programmed cell death. Although its direct molecular interactions are not fully characterized, functional studies indicate that OVCA2 influences apoptotic pathways that involve caspases and Bcl-2 family members. Loss of OVCA2 expression is associated with reduced apoptosis, leading to enhanced cell survival and proliferation. By disrupting OVCA2, this knockout model permits dissection of its role in apoptosis regulation and its crosstalk with core apoptotic machinery, including effector caspases such as caspase-3 and regulatory proteins like BAX and BCL-2.
In the context of AGS gastric cancer cells, OVCA2 knockout is predicted to abrogate its tumor-suppressive function, thereby creating a cellular environment with diminished apoptotic capacity. This model facilitates the exploration of how loss of OVCA2 contributes to gastric carcinogenesis, potentially revealing mechanisms of chemoresistance or metastatic progression. Additionally, given the gene??s initial association with ovarian cancer, the AGS knockout cells can serve as a comparative model for understanding tissue-specific tumor suppression mechanisms across different epithelial cancers.
Researchers can employ these OVCA2 knockout polyclonal cells in a variety of apoptosis-focused experiments, including flow cytometry using annexin V/propidium iodide staining to quantify apoptotic rates, MTS/MTT assays to evaluate cell viability, and colony formation assays to assess long-term proliferative capacity. Molecular analyses such as western blotting for cleaved caspase-3 and PARP, along with RT-qPCR profiling of apoptotic gene expression, will help delineate OVCA2??s impact on downstream signaling. This versatile tool is ideal for cancer biologists, pharmacologists, and tumor suppressor gene researchers aiming to characterize OVCA2 function and its therapeutic implications. For more detailed information or custom gene-editing services, please contact Ascent Research.
